Frank Rimerman Advisors LLC Has $2.14 Million Stock Holdings in Abbott Laboratories $ABT

Frank Rimerman Advisors LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 26.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 17,041 shares of the healthcare product maker’s stock after selling 6,009 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Abbott Laboratories were worth $2,135,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC raised its stake in shares of Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after acquiring an additional 162 shares during the last quarter. United Bank boosted its holdings in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after acquiring an additional 2,001 shares in the last quarter. Loomis Sayles & Co. L P grew its position in Abbott Laboratories by 37.4% during the 2nd quarter. Loomis Sayles & Co. L P now owns 47,552 shares of the healthcare product maker’s stock worth $6,468,000 after acquiring an additional 12,939 shares during the last quarter. Finally, Edgestream Partners L.P. acquired a new stake in Abbott Laboratories during the 2nd quarter valued at $404,000. 75.18% of the stock is owned by institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Precision Oncology tests are now integrated into Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers and ~4,700 providers the ability to order and receive Abbott test results inside their clinical workflow — a direct adoption catalyst for tests such as Oncotype DX, OncoExTra and Oncodetect that can lift diagnostics volume and recurring revenue. Abbott expands access to Precision Oncology
• Positive Sentiment: Abbott is a strategic investor in Whoop’s $575M Series G round (company valued at ~$10.1B). That stake gives Abbott optionality in wearable/consumer biometric data and potential commercial partnerships as Whoop scales globally and eyes an IPO — a complementary play to Abbott’s diabetes and consumer health franchises. Whoop raises $575M, adds Abbott as strategic investor
• Positive Sentiment: Industry research flags the global medical nutrition market growing to ~$31.1B by 2035, with Abbott named among key innovators — a favorable long-term demand backdrop for Abbott’s Nutrition segment once it stabilizes. Global Medical Nutrition Market to Reach USD 31.1 Billion by 2035
• Neutral Sentiment: Analyst note: BTIG trimmed its price target from $140 to $131 but maintained a Buy rating — a modest near-term view change but still a constructive stance implying upside from current levels. BTIG lowers ABT price target
• Neutral Sentiment: Recent analyst and media coverage highlights a mixed fundamental picture: Nutrition sales have pressured near-term growth, but Medical Devices (including FreeStyle Libre CGM and structural heart/electrophysiology businesses) remain strong; management is executing turnaround plans and pursuing the Exact Sciences acquisition — important long-term catalysts but with near-term execution risk. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Negative Sentiment: Price action & volatility: recent trading showed a pullback to near 52‑week lows amid sector rotation and nutrition weakness, which has pressured sentiment even though core businesses remain solid. Short-term selling and investor rotation remain risks. Abbott (ABT) Dips More Than Broader Market

Wall Street Analysts Forecast Growth

A number of research firms have commented on ABT. Evercore reduced their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Oppenheimer lowered their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Citigroup reduced their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Finally, The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $135.68.

Insiders Place Their Bets

In other news, EVP Elizabeth C. Cushman sold 263 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the sale, the executive vice president directly owned 38,573 shares of the company’s stock, valued at $4,458,267.34. This represents a 0.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last ninety days. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Trading Up 0.7%

ABT opened at $102.59 on Wednesday. The firm has a 50 day simple moving average of $110.05 and a 200 day simple moving average of $121.57. Abbott Laboratories has a fifty-two week low of $100.88 and a fifty-two week high of $139.06. The company has a market cap of $178.68 billion, a price-to-earnings ratio of 27.58, a price-to-earnings-growth ratio of 1.63 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories’s payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.